SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular Clinical Trial

Official title:

A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres®) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00503867
• Other study ID #: STX 0106
• Status: Terminated
• Phase: N/A
• Start date: July 18, 2007
• Est. completion date: March 9, 2010

Study information

• Verified date: November 2020
• Source: Sirtex Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to determine the safety and toxicity of treatment with SIR-Spheres® in patients with unresectable primary liver cancer or hepatocellular carcinoma (HCC). Other purposes of this study include assessment of the effect of treatment on overall survival, the length of time it takes for the disease to worsen, if and how the treatment affects the patient's quality of life, and if and how the cancer responds to the treatment.

Description:

This study is a multi-institutional, non-randomized pilot study that aims to assess the safety and toxicity of hepatic arterial radioembolization using SIR-Spheres yttrium-90 microspheres (SIR-Spheres microspheres) in the treatment of patients with unresectable primary hepatocellular carcinoma (HCC). The study aims to recruit 40 patients over a period of 24 months.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: March 9, 2010
• Est. primary completion date: March 9, 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• must have a confirmed diagnosis of HCC.
• at least 18 years of age.
• must have a confirmed diagnosis of HCC either by histological confirmation or, in a subject who exhibits a vascular liver mass in the presence of radiographically apparent cirrhosis, an alpha-fetoprotein (AFP) level greater than 500 International Units/milliliter (UI/ml).
• must present HCC that is not amenable to surgical resection or immediate liver transplantation, or that is not optimally treatable with local ablative techniques such as radio-frequency ablation due to its size, extent or presence of cirrhosis.
• must present measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as greater than or equal to 10 mm with spiral CT scan or greater than or equal to 20 mm using conventional techniques (CT, MRI).
• must present with a whole-liver tumor burden of greater than or equal to 15% and less than or equal to 70%
• must have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.
• must have normal organ and marrow function Exclusion criteria: Includes both the listed contraindications to SIR-Spheres® and the exclusion criteria

specific to the setting of this investigational study:

• hepatic artery directed therapy within the previous 6 months.
• chemotherapy within the previous 4 weeks
• have not recovered from adverse events due to agents administered previously
• Prior external hepatic radiation therapy for HCC, more than two prior systemic chemotherapy regimes for HCC or any other concomitant therapy for HCC
• Currently receiving any other investigational agents for the treatment of their cancer.
• Any extra-hepatic metastases other than metastatic disease found in the lung, bone and/or abdominal lymph nodes that are not otherwise life limiting.
• Any other concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least five years.
• Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
• Any of the following contraindications to angiography and selective visceral

catheterization:

• Bleeding diathesis
• Severe peripheral vascular disease
• Portal hypertension with hepatofugal flow
• Female subjects who are pregnant or currently breastfeeding.
• Refusal or inability to use effective means of contraception in men or women of childbearing potential.
• Current enrollment in any other investigational drug or device study.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatoma

Intervention

Device:
• SIR-Spheres microspheres
SIR-Spheres Yttrium-90 microspheres

Locations

Country	Name	City	State
United States	The Liver Institute at Methodist Dallas	Dallas	Texas
United States	MD Anderson Cancer Center	Houston	Texas
United States	Thomas Jefferson University - Kimmel Cancer Center	Philadelphia	Pennsylvania
United States	UPMC Liver Cancer Center	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Sirtex Medical

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Adverse Events Grade 3 or Higher	Using the National Cancer Institute Common Terminology Criteria (NCI-CTC) version 3.0 as recorded in the case report form.	From date of enrollment until the date of death from any cause assessed up 24 weeks.
Secondary	Time to Disease Progression	Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.
Secondary	Tumor Response Rate	Tumour response rates estimated by the proportion of patients with a best response of CR, PR or SD by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) with corresponding exact 90% confidence limits being reported. Per RECIST v1.0 for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.
Secondary	Change From Baseline in Health-related Quality of Life		52 weeks
Secondary	Overall Survival	Overall Survival is defined as the time interval between the date of enrollment and the date of death from any cause.	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.